您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > VPS34 inhibitor 1(Compound 19,PIK-III analogue)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
VPS34 inhibitor 1(Compound 19,PIK-III analogue)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
VPS34 inhibitor 1(Compound 19,PIK-III analogue)图片
CAS NO:1383716-46-8
包装与价格:
包装价格(元)
1 mg电议
2 mg电议
5 mg电议
10 mg电议
25 mg电议
50 mg电议
100 mg电议
200 mg电议

产品名称
PIK-III analogue
VPS34 inhibitor 1 (Compound 19, PIK-III analogue)
产品介绍
VPS34 inhibitor 1 (Compound 19, PIK-III analogue) 是一种有效的选择性VPS34抑制剂( IC50 : 15 nM)。

产品描述

VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is a potent and selective inhibitor of VPS34( IC50 : 15 nM)

体外活性

VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is extraordinarily selective over other lipid and protein kinases. The ability of compound 19 to prevent the degradation of autophagy substrates p62, NCOA4, NBR1, NDP52, and FTH1 is similar to PIK-III. In addition, treatment of cells with compound 19 leads to an increase in the lipidated and nonlipidated forms of LC3 similar to previous reports using PIK-III.

体内活性

The pharmacokinetic profile of analogue 19 is determined in C57BL/6 mice.?After oral administration at 10 mg/kg, the compound is rapidly absorbed and showed moderate mean systemic clearance (30 mL/min/kg, approximately 33% of hepatic blood flow), with good oral bioavailability (F% = 47).?Based on these PK parameters and the cellular activity, compound 19 constitutes a suitable candidate for in vivo studies.?Upon oral administration of compound 19 at 50 mg/kg twice a day (BID) for 7 days, LC3-II accumulates consistent with reduced autophagic capacity in time-dependent manner.?It inhibits autophagy in vivo.

细胞实验

Cell lines: U2OS cells.Concentrations: 0, 1, 5, 10 μM. Incubation Time: 24 h .Method: For inhibitor assay, cells are plated and the following day when cells had reached 90%, are treated with dimethyl sulfoxide (DMSO, vehicle) or the indicated concentration of PIK-III or Compound 19, both dissolved in DMSO. 24 hours later, cells are lysed in RIPA supplemented with 1% SDS and mini-EDTA protease inhibitors, homogenized by passage through a Qiashredder column and the protein is quantified by DC Lowry protein assay.

动物实验

Animal Models: C57BL/6 Mice. Formulation: PG (20% v/v). Dosages: 10 mg/kg(p.o.) or 2 mg/kg(I.V.) .Administration: oral administration or I.V.

Cas No.

1383716-46-8

分子式

C21H25N7O

分子量

391.479

别名

PIK-III analogue;VPS34 inhibitor 1 (Compound 19, PIK-III analogue)

储存和溶解度

DMSO:78 mg/mL (199.25 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years